Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021)
Karyopharm Therapeutics' (KPTI) quarterly Asset Writedowns and Impairment came in at $200000.0 in Q3 2021, up 100.0% on a QoQ basis from $100000.0 in Q2 2021.
Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 2 years of Asset Writedowns and Impairment data on file, last reported at $200000.0 in Q3 2021.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $200000.0 in Q3 2021, while the trailing twelve-month figure through Mar 2022 was $382000.0 (down 7.06% YoY) and the FY2020 annual result came in at $329000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment rose to $200000.0 in Q3 2021, from $100000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $329000.0 in Q4 2020 to a low of $82000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 200,000.00 |
| Sep 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 82,000.00 |
| Mar 31, 2021 | 82,000.00 |
| Dec 31, 2020 | 329,000.00 |
| Dec 31, 2020 | 329,000.00 |